Brief: Phio Pharmaceuticals, AgonOx Inc Announce Collaboration on Development of Cancer Immunotherapies
01/03/2021 13:53
March 1 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS CORP - CO, AGONOX, INC. ANNOUNCE
COLLABORATION ON CLINICAL DEVELOPMENT OF NOVEL T CELL-BASED
CANCER IMMUNOTHERAPIES
* PHIO PHARMACEUTICALS CORP - AGONOX WILL RECEIVE FINANCIAL
SUPPORT FOR CLINICAL TRIAL FROM PHIO
* PHIO PHARMACEUTICALS CORP - CO IS ENTITLED TO CERTAIN
FUTURE
DEVELOPMENT MILESTONES & SALES RELATED ROYALTY PAYMENTS FROM
AGONOX'S DP TIL TECHNOLOGY
Source text for Eikon: ID:nPn9n30xa
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing